CLSN Celsion Corp

Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

As of 10/15/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/01/2001
Outstanding shares:  86,557,736
Average volume:  966,567
Market cap:   $85,770,061
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    15117N503
ISIN:        US15117N5032
Valuation   (See tab for details)
PE ratio:   -3.90
PB ratio:   1.35
PS ratio:   171.54
Return on equity:   -34.69%
Net income %:   -4,444.23%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy